The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragment thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.